BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sisto M, Lisi S, D'Amore M, Lofrumento DD. Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome. Immunology 2014;143:42-51. [PMID: 24655025 DOI: 10.1111/imm.12288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lappas M. RKIP is decreased in laboring myometrium and modulates inflammation-induced pro-labor mediators. Reproduction 2017;153:545-53. [PMID: 28280133 DOI: 10.1530/REP-17-0006] [Reference Citation Analysis]
2 Gabriela-Freitas M, Pinheiro J, Raquel-Cunha A, Cardoso-Carneiro D, Martinho O. RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer. Biomolecules 2019;9:E769. [PMID: 31766768 DOI: 10.3390/biom9120769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Verstappen GM, Kroese FG, Vissink A, Bootsma H. Pharmacotherapy for managing extraglandular symptoms of primary Sjögren’s syndrome. Expert Opinion on Orphan Drugs 2015;3:125-39. [DOI: 10.1517/21678707.2015.1010510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
4 Sisto M, Barca A, Lofrumento DD, Lisi S. Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20. Clin Exp Immunol 2016;184:183-96. [PMID: 26724675 DOI: 10.1111/cei.12764] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
5 Zhao J, Wenzel S. Interactions of RKIP with inflammatory signaling pathways. Crit Rev Oncog 2014;19:497-504. [PMID: 25597359 DOI: 10.1615/critrevoncog.2014011950] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zaravinos A, Bonavida B, Chatzaki E, Baritaki S. RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact. Cancers (Basel) 2018;10:E287. [PMID: 30149591 DOI: 10.3390/cancers10090287] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 7.8] [Reference Citation Analysis]
7 Yu J, Canalis E. The Hajdu Cheney mutation sensitizes mice to the osteolytic actions of tumor necrosis factor α. J Biol Chem 2019;294:14203-14. [PMID: 31371452 DOI: 10.1074/jbc.RA119.009824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sisto M, Ribatti D, Lisi S. Understanding the Complexity of Sjögren's Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms. J Clin Med 2020;9:E2821. [PMID: 32878252 DOI: 10.3390/jcm9092821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Touboul R, Baritaki S, Zaravinos A, Bonavida B. RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity. Cancers (Basel) 2021;13:6247. [PMID: 34944867 DOI: 10.3390/cancers13246247] [Reference Citation Analysis]
10 Zhan T, Wang B, Fu J, Shao Y, Ye L, Shi H, Zheng L. Artesunate inhibits Sjögren's syndrome-like autoimmune responses and BAFF-induced B cell hyperactivation via TRAF6-mediated NF-κB signaling. Phytomedicine 2021;80:153381. [PMID: 33086170 DOI: 10.1016/j.phymed.2020.153381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Yin R, Liu X, Bi Y, Xie G, Zhang P, Meng X, Ai L, Xu R, Sun Y, Stoeger T, Ding Z. Expression of Raf kinase inhibitor protein is downregulated in response to Newcastle disease virus infection to promote viral replication. J Gen Virol 2015;96:2579-86. [PMID: 26297355 DOI: 10.1099/jgv.0.000228] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]